Literature DB >> 27784155

Self-Targeted Polysaccharide Prodrug Suppresses Orthotopic Hepatoma.

Di Li1,2, Weiguo Xu1, Pengqiang Li1, Jianxun Ding1, Zhiliang Cheng3, Li Chen2, Lesan Yan3, Xuesi Chen1.   

Abstract

Self-targetability is an emerging targeting strategy for polymer nanocarriers with facile preparation and high targeting efficiency. An acid-sensitive dextran-doxorubicin prodrug (Dex-g-DOX) has been synthesized and used as a self-targeted drug delivery system for the treatment of orthotopic hepatoma. The polysaccharide prodrug exhibits ultraselective accumulation in cancerous liver tissue, acid-sensitive DOX release within cells, and high antitumor efficacy in vitro and in vivo. Therefore, Dex-g-DOX demonstrates great potential for chemotherapy of orthotopic hepatoma.

Entities:  

Keywords:  chemotherapy; orthotopic hepatoma; polysaccharide; prodrug; self-targetability

Mesh：

Substances：

Year:  2016        PMID： 27784155      PMCID： PMC5464407          DOI： 10.1021/acs.molpharmaceut.6b00747

Source DB:  PubMed          Journal:  Mol Pharm        ISSN： 1543-8384            Impact factor:   4.939


  11 in total

1.  Versatile preparation of intracellular-acidity-sensitive oxime-linked polysaccharide-doxorubicin conjugate for malignancy therapeutic.

Authors:  Weiguo Xu; Jianxun Ding; Chunsheng Xiao; Lingyu Li; Xiuli Zhuang; Xuesi Chen
Journal:  Biomaterials       Date:  2015-03-30       Impact factor: 12.479

Review 2.  Targeted polymer-drug conjugates: Current progress and future perspective.

Authors:  Hongyan Xu; Haifeng Ma; Peimin Yang; Xia Zhang; Xiangxia Wu; Weidong Yin; Hui Wang; Dongmei Xu
Journal:  Colloids Surf B Biointerfaces       Date:  2015-10-09       Impact factor: 5.268

3.  Acid-labile boronate-bridged dextran-bortezomib conjugate with up-regulated hypoxic tumor suppression.

Authors:  Weiguo Xu; Jianxun Ding; Lingyu Li; Chunsheng Xiao; Xiuli Zhuang; Xuesi Chen
Journal:  Chem Commun (Camb)       Date:  2015-04-21       Impact factor: 6.222

4.  Polymeric conjugates for drug delivery.

Authors:  Nate Larson; Hamidreza Ghandehari
Journal:  Chem Mater       Date:  2012-01-04       Impact factor: 9.811

5.  An inducible hepatocellular carcinoma model for preclinical evaluation of antiangiogenic therapy in adult mice.

Authors:  Anja Runge; Junhao Hu; Matthias Wieland; Jan-Philip Bergeest; Carolin Mogler; André Neumann; Cyrill Géraud; Bernd Arnold; Karl Rohr; Dorde Komljenovic; Peter Schirmacher; Sergij Goerdt; Hellmut G Augustin
Journal:  Cancer Res       Date:  2014-06-06       Impact factor: 12.701

6.  Enhancement of anti-tumor activity of hybrid peptide in conjugation with carboxymethyl dextran via disulfide linkers.

Authors:  Arong Gaowa; Tomohisa Horibe; Masayuki Kohno; Yasuhiko Tabata; Hiroshi Harada; Masahiro Hiraoka; Koji Kawakami
Journal:  Eur J Pharm Biopharm       Date:  2015-03-20       Impact factor: 5.571

Review 7.  Polymer-drug conjugates: origins, progress to date and future directions.

Authors:  Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-11-02       Impact factor: 15.470

8.  Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model.

Authors:  Kui Wang; Forrest M Kievit; Jonathan G Sham; Mike Jeon; Zachary R Stephen; Arvind Bakthavatsalam; James O Park; Miqin Zhang
Journal:  Small       Date:  2015-12-07       Impact factor: 13.281

Review 9.  Nanoparticle-blood interactions: the implications on solid tumour targeting.

Authors:  James Lazarovits; Yih Yang Chen; Edward A Sykes; Warren C W Chan
Journal:  Chem Commun (Camb)       Date:  2015-02-18       Impact factor: 6.222

Review 10.  Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?

Authors:  Hisataka Kobayashi; Rira Watanabe; Peter L Choyke
Journal:  Theranostics       Date:  2013-12-11       Impact factor: 11.556
View more
  6 in total

1.  Novel Core-Interlayer-Shell DOX/ZnPc Co-loaded MSNs@ pH-Sensitive CaP@PEGylated Liposome for Enhanced Synergetic Chemo-Photodynamic Therapy.

Authors:  Jinyuan Ma; Hongjie Wu; Yang Li; Zehua Liu; Guihua Liu; Yuxin Guo; Zhenqing Hou; Qingliang Zhao; Dengyue Chen; Xuan Zhu
Journal:  Pharm Res       Date:  2018-02-08       Impact factor: 4.200

Review 2.  Immunomodulatory Nanosystems.

Authors:  Xiangru Feng; Weiguo Xu; Zhongmin Li; Wantong Song; Jianxun Ding; Xuesi Chen
Journal:  Adv Sci (Weinh)       Date:  2019-06-21       Impact factor: 16.806

3.  Poly((D,L)lactic-glycolic)acid-star glucose nanoparticles for glucose transporter and hypoglycemia-mediated tumor targeting.

Authors:  Ju-Hwan Park; Hyun-Jong Cho; Dae-Duk Kim
Journal:  Int J Nanomedicine       Date:  2017-10-11

Review 4.  Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models.

Authors:  Qilong Wang; Ping Zhang; Zhongmin Li; Xiangru Feng; Chengyue Lv; Huaiyu Zhang; Haihua Xiao; Jianxun Ding; Xuesi Chen
Journal:  Theranostics       Date:  2019-02-20       Impact factor: 11.556

5.  TGF‑β inhibitor RepSox suppresses osteosarcoma via the JNK/Smad3 signaling pathway.

Authors:  Dengwei He; Jiawei Gao; Lin Zheng; Shijie Liu; Lin Ye; Hehuan Lai; Bin Pan; Wenzheng Pan; Chao Lou; Zhenzhong Chen; Shunwu Fan
Journal:  Int J Oncol       Date:  2021-09-17       Impact factor: 5.650

6.  Facile Fabrication of Reduction-Responsive Supramolecular Nanoassemblies for Co-delivery of Doxorubicin and Sorafenib toward Hepatoma Cells.

Authors:  Qingqing Xiong; Mangmang Cui; Ge Yu; Jian Wang; Tianqiang Song
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.